診断用エクソソーム・バイオマーカーの世界市場

診断用エクソソーム・バイオマーカーの世界市場は2030年までに3億3,040万米ドルに達する見込み

2024年に1億2,240万米ドルと推定される診断用エクソソーム・バイオマーカーの世界市場は、2024年から2030年にかけてCAGR 18.0%で成長し、2030年には3億3,040万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである試薬は、CAGR 15.5％を記録し、分析期間終了時には1億2,040万米ドルに達すると予測されています。キットセグメントの成長率は、分析期間中CAGR 21.3％と推定されます。

米国市場は3,340万米ドルと推定、中国はCAGR24.1％で成長予測

米国の診断用エクソソーム・バイオマーカー市場は、2024年に3,340万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRが24.1％で、2030年には市場規模が7,510万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.6％と15.9％と予測されています。欧州では、ドイツがCAGR約14.9%で成長すると予測されています。

世界の診断用エクソソーム・バイオマーカー市場- 主要動向と促進要因のまとめ

なぜエクソソームバイオマーカーが疾患診断の未来を変えるのか？

エクソソームバイオマーカーは、非侵襲的なリキッドバイオプシー（液体生検）技術を通じて疾患メカニズムに関するこれまでにない洞察を提供し、精密医療における画期的な診断ツールとして急速に台頭しています。エクソソームとは、細胞から血液、唾液、尿、脳脊髄液などの体液中に分泌されるナノサイズの細胞外小胞です。これらの小胞は、タンパク質、脂質、mRNA、マイクロRNA、DNA断片など、豊富な分子カーゴを運び、その由来細胞の生理的・病理的状態を反映します。エクソソームは全身を循環し、腫瘍や炎症組織、損傷組織など様々な組織型に由来するため、疾患の早期発見のためのバイオマーカーを入手しやすく、安定で、特異的なキャリアーとして機能します。エクソソームに基づく診断により、乳がん、肺がん、前立腺がん、膵臓がんなどの早期発見が可能になり、従来の画像診断や組織生検で発見される前に発見されることも少なくないです。がんに限らず、エクソソームバイオマーカーは神経変性疾患、心血管疾患、感染症、さらには妊娠に関連する合併症の診断にも利用されつつあります。低侵襲の診断ツールであるエクソソーム分析は、患者のコンプライアンス、繰り返し検査、リアルタイムの疾患モニタリングにおいて大きな利点を提供し、個別化医療と予防医療へのシフトにおける礎石として位置づけられています。

技術革新はエクソソームベースの診断の精度とアクセシビリティをどのように高めているか？

エクソソームの単離、精製、特性解析における技術的進歩は、エクソソームバイオマーカー診断の信頼性と拡張性を急速に高めています。かつてはエクソソーム単離のゴールドスタンダードと考えられていた従来の超遠心分離法は、マイクロ流体工学、サイズ排除クロマトグラフィー、イムノアフィニティー捕捉、音響選別などのより高速で効率的な技術によって補完され、取って代わられつつあります。これらの技術は、サンプル処理時間を短縮しながら純度と収量を向上させ、エクソソームバイオマーカー検出を臨床ワークフローに適合したものにしています。ナノ粒子追跡分析（NTA）、動的光散乱（DLS）、次世代シーケンシング（NGS）などの分析プラットフォームは、エクソソーム内容物の高分解能プロファイリングを可能にし、バイオセンサーやラボオンチップ装置は、ポイントオブケアのエクソソーム診断を現実に近づけています。機械学習アルゴリズムもまた、複雑なエクソソームデータを解釈し、より高い精度で疾患特異的シグネチャーを同定するために、診断プラットフォームに統合されつつあります。さらに現在では、多重化技術によって1つのサンプルから複数のバイオマーカーを同時に検出することが可能になり、患者の不快感を最小限に抑えながら診断力を高めています。技術統合が進むにつれて、エクソソーム解析のコストは低下し、その利用可能性は研究環境から日常臨床へと拡大すると予想されます。このような技術革新は、診断感度と特異度の向上を促進するだけでなく、早期発見、疾患分類、治療層別化のための新たな可能性を解き放ちつつあります。

なぜ臨床・研究界はエクソソームバイオマーカーに注目しているのか？

臨床および研究コミュニティにおけるエクソソームバイオマーカーへの注目の高まりは、従来の診断法に伴う限界を克服する可能性に由来します。例えば腫瘍学では、従来の組織生検は侵襲的で、時には実行不可能であり、腫瘍生物学の静的なスナップショットしか得られないことが多いです。これとは対照的に、エクソソームは、日常的なリキッドバイオプシーによって、疾患の進行を動的かつ長期的に見ることができます。この機能により、臨床医は腫瘍の進化を追跡し、治療反応をモニターし、再発の初期徴候をより頻繁に、より少ない患者負担で検出することができます。アルツハイマー病やパーキンソン病のような神経変性疾患では、診断が遅れたり不確実であったりすることが多いが、脳脊髄液や血漿から発見されるエクソソームバイオマーカーは、臨床症状が現れる何年も前に、早期の病理学的変化を明らかにすることができます。同様に、心血管系疾患では、エクソソーム由来のマイクロRNAやタンパク質が心筋ストレス、血管炎症、プラークの不安定性の指標となり、従来の脂質プロファイルを超える予後予測価値を提供します。研究コミュニティはまた、感染症、自己免疫疾患、臓器移植拒絶反応におけるエクソソームバイオマーカーの役割についても探求しています。製薬会社と学術機関は、エクソソームベースの診断キットを開発し、医薬品開発パイプラインに組み込むために積極的に協力しています。この機運は、規制当局の関心の高まりと公衆衛生機関からの資金提供によってさらに後押しされており、早期介入と個別化医療のためのバイオマーカー主導型診断へのパラダイムシフトを浮き彫りにしています。

診断用エクソソーム・バイオマーカー市場の世界的成長を加速する主な促進要因は？

診断用エクソソーム・バイオマーカー市場の成長は、科学的イノベーション、市場ダイナミクス、規制の進化、臨床需要など、相互に関連するいくつかの要因によって促進されています。特にがん、神経変性疾患、心血管疾患などの慢性的で複雑な疾患が世界的に増加しており、早期かつ正確で低侵襲な診断アプローチが求められています。エクソソーム・バイオマーカーは、高い分子特異性と疾患の初期段階での検出能力を提供することで、こうしたニーズに応えています。分離・検出ツールの技術的進歩により、エクソソームを用いた検査の臨床的有用性は著しく向上し、バイオテクノロジー企業や診断会社から大きな投資を集めています。さらに、精密医療イニシアチブの普及とコンパニオン診断への注目の高まりが、エクソソームバイオマーカーの採用を後押ししています。FDAやEMAを含む規制機関は、バイオマーカーの検証・承認に向けた明確な道筋を確立し始めており、イノベーションを促進し、市場参入の障壁を減らしています。産学連携や複数施設での臨床試験がエクソソーム診断のエビデンスベースを拡大し、ゲノミクスやプロテオミクスの政府出資プロジェクトが研究を加速させています。最後に、非侵襲的な検査ソリューションに対する患者の意識と需要が、特に外来患者や在宅医療における市場の成長に寄与しています。これらの力を総合すると、エクソソーム・バイオマーカー市場の堅調な拡大が促進され、診断と個別化ヘルスケアの将来における重要なプレーヤーとして位置づけられています。

セグメント

製品タイプ（試薬、キット、血清／血漿キット、尿キット、ソフトウェア）、用途（神経変性疾患、腫瘍学、代謝性疾患、その他用途）、最終用途（がん研究機関、病院、診断センター、その他最終用途）

調査対象企業の例（注目の32社）

• Aethlon Medical, Inc.
• AMSBIO
• Bio-Techne Corporation
• BioVision, Inc.
• Capital Biosciences, Inc.
• Capricor Therapeutics, Inc.
• Codiak BioSciences, Inc.
• Direct Biologics LLC
• Evox Therapeutics Ltd
• Exo Biologics
• Exogenus Therapeutics
• Exosome Diagnostics, Inc.
• Exosomics S.p.A.
• Hitachi Chemical Diagnostics, Inc.
• INOVIQ Ltd
• Izon Science Ltd
• NanoFCM Inc.
• NanoSomix, Inc.
• QIAGEN N.V.
• System Biosciences, LLC

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Diagnostic Exosome Biomarkers Market to Reach US$330.4 Million by 2030

The global market for Diagnostic Exosome Biomarkers estimated at US$122.4 Million in the year 2024, is expected to reach US$330.4 Million by 2030, growing at a CAGR of 18.0% over the analysis period 2024-2030. Reagents, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$120.4 Million by the end of the analysis period. Growth in the Kits segment is estimated at 21.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$33.4 Million While China is Forecast to Grow at 24.1% CAGR

The Diagnostic Exosome Biomarkers market in the U.S. is estimated at US$33.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$75.1 Million by the year 2030 trailing a CAGR of 24.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.6% and 15.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.9% CAGR.

Global Diagnostic Exosome Biomarkers Market - Key Trends & Drivers Summarized

Why Are Exosome Biomarkers Transforming the Future of Disease Diagnosis?

Exosome biomarkers are rapidly emerging as a revolutionary diagnostic tool in precision medicine, offering unprecedented insights into disease mechanisms through non-invasive liquid biopsy techniques. Exosomes are nano-sized extracellular vesicles secreted by cells into bodily fluids such as blood, saliva, urine, and cerebrospinal fluid. These vesicles carry a wealth of molecular cargo-proteins, lipids, mRNAs, microRNAs, and DNA fragments-that reflect the physiological and pathological state of their originating cells. Because exosomes circulate systemically and originate from various tissue types, including tumors and inflamed or damaged tissues, they serve as accessible, stable, and specific carriers of biomarkers for early disease detection. Their role is particularly transformative in oncology, where exosome-based diagnostics are enabling early identification of cancers such as breast, lung, prostate, and pancreatic, often before conventional imaging or tissue biopsy would reveal them. Beyond cancer, exosomal biomarkers are gaining traction in the diagnosis of neurodegenerative diseases, cardiovascular disorders, infectious diseases, and even pregnancy-related complications. As a minimally invasive diagnostic tool, exosome analysis offers significant advantages in patient compliance, repeat testing, and real-time disease monitoring, positioning it as a cornerstone in the shift toward personalized and preventive healthcare.

How Are Technological Innovations Enhancing the Accuracy and Accessibility of Exosome-Based Diagnostics?

Technological advancements in isolation, purification, and characterization of exosomes are rapidly advancing the reliability and scalability of exosome biomarker diagnostics. Traditional ultracentrifugation methods, once considered the gold standard for exosome isolation, are being supplemented and replaced by faster, more efficient techniques such as microfluidics, size exclusion chromatography, immunoaffinity capture, and acoustic sorting. These technologies are improving purity and yield while reducing sample processing time, making exosome biomarker detection more compatible with clinical workflows. Analytical platforms such as nanoparticle tracking analysis (NTA), dynamic light scattering (DLS), and next-generation sequencing (NGS) are enabling high-resolution profiling of exosomal contents, while biosensors and lab-on-chip devices are bringing point-of-care exosome diagnostics closer to reality. Machine learning algorithms are also being integrated into diagnostic platforms to interpret complex exosomal data and identify disease-specific signatures with greater precision. Moreover, multiplexing technologies now allow simultaneous detection of multiple biomarkers from a single sample, increasing diagnostic power while minimizing patient discomfort. As technological integration continues, the cost of exosome analysis is expected to decline, expanding its accessibility beyond research settings into routine clinical practice. These innovations are not only driving improved diagnostic sensitivity and specificity but are also unlocking new possibilities for early detection, disease classification, and treatment stratification.

Why Is the Clinical and Research Community Focusing Intensely on Exosome Biomarkers?

The growing focus on exosome biomarkers within the clinical and research communities stems from their potential to overcome limitations associated with traditional diagnostic methods. In oncology, for example, conventional tissue biopsies are invasive, sometimes infeasible, and often provide only a static snapshot of tumor biology. In contrast, exosomes offer a dynamic, longitudinal view of disease progression through routine liquid biopsies. This capability allows clinicians to track tumor evolution, monitor treatment response, and detect early signs of recurrence with greater frequency and less patient burden. In neurodegenerative conditions like Alzheimer’s and Parkinson’s disease, where diagnosis is often delayed or uncertain, exosomal biomarkers found in cerebrospinal fluid or plasma can reveal early pathological changes-years before clinical symptoms manifest. Similarly, in cardiovascular diseases, exosome-derived microRNAs and proteins serve as indicators of myocardial stress, vascular inflammation, and plaque instability, offering prognostic value beyond traditional lipid profiles. The research community is also exploring exosome biomarkers for their role in infectious diseases, autoimmune disorders, and organ transplant rejection. Pharmaceutical companies and academic institutions are actively collaborating to develop exosome-based diagnostic kits and integrate them into drug development pipelines. This momentum is further supported by growing regulatory interest and funding from public health bodies, underscoring the paradigm shift toward biomarker-driven diagnostics for early intervention and personalized medicine.

What Are the Key Drivers Accelerating Global Growth in the Diagnostic Exosome Biomarkers Market?

The growth in the diagnostic exosome biomarkers market is being fueled by several interrelated factors spanning scientific innovation, market dynamics, regulatory evolution, and clinical demand. A primary driver is the global rise in chronic and complex diseases-particularly cancers, neurodegenerative conditions, and cardiovascular disorders-that require early, precise, and minimally invasive diagnostic approaches. Exosome biomarkers meet these needs by offering a high level of molecular specificity and the ability to detect disease at its earliest stages. Technological progress in isolation and detection tools has significantly improved the clinical viability of exosome-based tests, attracting major investments from biotechnology firms and diagnostic companies. Furthermore, the proliferation of precision medicine initiatives and the increased focus on companion diagnostics are propelling exosome biomarker adoption, as these tools can help tailor therapies based on individual molecular profiles. Regulatory bodies, including the FDA and EMA, are beginning to establish clearer pathways for biomarker validation and approval, encouraging innovation and reducing barriers to market entry. Academic-industry collaborations and multi-institutional clinical trials are expanding the evidence base for exosome diagnostics, while government-funded projects in genomics and proteomics are accelerating research. Finally, patient awareness and demand for non-invasive testing solutions are contributing to market growth, especially in outpatient and home-based care settings. Collectively, these forces are driving a robust expansion of the exosome biomarkers market, positioning it as a key player in the future of diagnostics and personalized healthcare.

SCOPE OF STUDY:

The report analyzes the Diagnostic Exosome Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Reagents, Kits, Serum / Plasma Kits, Urine Kits, Software); Application (Neurodegenerative Disorders, Oncology, Metabolic Disorders, Other Applications); End-Use (Cancer Institutes, Hospitals, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Aethlon Medical, Inc.
• AMSBIO
• Bio-Techne Corporation
• BioVision, Inc.
• Capital Biosciences, Inc.
• Capricor Therapeutics, Inc.
• Codiak BioSciences, Inc.
• Direct Biologics LLC
• Evox Therapeutics Ltd
• Exo Biologics
• Exogenus Therapeutics
• Exosome Diagnostics, Inc.
• Exosomics S.p.A.
• Hitachi Chemical Diagnostics, Inc.
• INOVIQ Ltd
• Izon Science Ltd
• NanoFCM Inc.
• NanoSomix, Inc.
• QIAGEN N.V.
• System Biosciences, LLC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Diagnostic Exosome Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Liquid Biopsy Technologies Throws the Spotlight on Exosome-Based Biomarker Discovery
  • Growth in Cancer Precision Medicine Accelerates Use of Exosome-Derived RNA and Protein Signatures
  • OEM Focus on Early Disease Detection Supports R&D in Non-Invasive Exosomal Diagnostic Assays
  • Push Toward Real-Time and Longitudinal Monitoring Propels Integration of Exosome Analysis in Clinical Trials
  • Expansion of Companion Diagnostics Drives Innovation in Tumor-Specific Exosome Profiling Tools
  • Technological Advancements in Isolation and Purification Enhance Reproducibility of Exosome Biomarker Tests
  • Increased Use in Neurodegenerative and Inflammatory Disease Research Broadens Diagnostic Applications
  • Emergence of AI and Bioinformatics Solutions Supports Analysis of Complex Exosome-Derived Data Sets
  • Development of Multiplexed Detection Systems Enables Simultaneous Profiling of Multiple Biomarker Types
  • Push for Minimally Invasive Prenatal Testing Expands Interest in Fetal Exosome Biomarkers
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Diagnostic Exosome Biomarkers Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Diagnostic Exosome Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Diagnostic Exosome Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Serum / Plasma Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Serum / Plasma Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Serum / Plasma Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Urine Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Urine Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Urine Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Cancer Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Cancer Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Cancer Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Neurodegenerative Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Neurodegenerative Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Neurodegenerative Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• JAPAN
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• CHINA
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 71: China Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• EUROPE
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Diagnostic Exosome Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Diagnostic Exosome Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• FRANCE
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 92: France Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• GERMANY
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 119: UK Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Diagnostic Exosome Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Diagnostic Exosome Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• INDIA
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 176: India Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Diagnostic Exosome Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Diagnostic Exosome Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Diagnostic Exosome Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Diagnostic Exosome Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030
• AFRICA
  • Diagnostic Exosome Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Diagnostic Exosome Biomarkers by Product Type - Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Diagnostic Exosome Biomarkers by Product Type - Percentage Breakdown of Value Sales for Reagents, Kits, Serum / Plasma Kits, Urine Kits and Software for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Diagnostic Exosome Biomarkers by End-Use - Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Diagnostic Exosome Biomarkers by End-Use - Percentage Breakdown of Value Sales for Cancer Institutes, Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Diagnostic Exosome Biomarkers by Application - Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Diagnostic Exosome Biomarkers by Application - Percentage Breakdown of Value Sales for Neurodegenerative Disorders, Oncology, Metabolic Disorders and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION